Quarterly Report – Period To 31 March 2024

Orthocell has today published its Quarterly Report for the period ended 31 March 2024. Highlights for this Quarter include: ● Increasing revenue driven by growth in new product sales. Year to date revenue of $4.88 million is up 40.7% from $3.47 million for the same period last year. ● Successful completion of a $3.5 million strategic placement ● Strong balance sheet with $20.1m cash at bank at the end of the quarter ● Strengthening the Board with appointment of the Hon Kim Beazley AC ● Successful completion of all nerve repair surgeries in Remplir™ US market authorisation study ● Submission of Singapore Regulatory Application for Remplir™ in February 2024 Orthocell Managing Director, Paul Anderson, said: “Orthocell has completed a very solid quarter, growing revenues whilst strengthening the balance sheet and share register. I am very pleased with the performance of our distribution partners and the continued increase in product adoption. With a highly respected and experienced Board now in place, we are in a strong position to continue to gain commercial traction and drive Remplir, our breakthrough nerve repair device, into global markets.” Click here to read today’s ASX release.